[ad_1]
A team of Israeli scientists surprised the medical community by announcing that they had found the first and definitive cancer treatment . The announcement was made soon after the date of awareness of the disease, World Cancer Day, celebrated on February 4th.
In an interview with the newspaper The Jerusalem Post at the end of January, researchers – who are part of the startup Accelerated Evolution Biotechnologies (AEBI) – estimated that the new approach would be available within a maximum of one year to be tested in humans and would result in little or no side effects for patients
In addition, the treatment would last a few weeks, would be less expensive than most currently available approaches and could be targeted globally (for many patients with different cancers) and with a personalized application. The interview of Ilan Morad, CEO of the start-up, and Dan Aridor, owner of the company, relayed the medical community – especially those related to the fight against cancer –
"
There is no data published in the medical literature
Leonard Lichtenfeld, deputy medical director of the American Cancer Society, published, in a blog within the among the points to be considered, there to the fact that: "this new [da cura do câncer] is based on limited information given by researchers and the society that develops the technology. .
Israeli developers themselves claimed in the local newspaper interview that they had not published any of them. information because they could not afford the disclosure. However, doctors also dispute it:
"There are now a number of ways to disseminate data and make them available to the medical community, some for free," says immunologist and director Kenneth Gollob. of Immuno. -Ocology of the AC Camargo de São Paulo Cancer Center.
Results obtained only in laboratory in mice and human cells
It is still too early to know if this discovery will actually change the direction of treatment. There are hundreds of clinical studies in different fields of medicine, but mainly in the field of oncology, which have reached the stage of badysis of substances and treatments in mice or mice. human cells in the laboratory, but do not progress .
According to Kenneth Gollob, an immunologist, new drugs or treatments do not progress as much because of the difference in toxicity as the change in efficacy between the animals / human cells and the actual patients.
19659002] "In animals, the substance may be of low toxicity, but in humans it may be higher.The human metabolism is also very different from that of the mouse, which may improve the ability of the human body to improve its metabolism. The human biological environment is another problem that can hinder progress: sometimes it affects the disease of the mouse, but not when it touches the man. "
May It Work? Yes
In the question of "if", there is also a positive view of the study. "It can turn out to be something spectacular, so you can not even say yes, it's going to heal or not, it's not going to heal." According to immunologist Kenneth Gollob, there is no way to Judge, because there is no information about it.
According to what few Israeli researchers have divulged about "cancer treatment", they claim to have developed a kind of "antibiotic" , based on SoAP technology, part of the technology group called Phase Display, or phage display, in free translation.
Gollob explains that "phage display" technologies are not new and many searches are working with this approach to cancer, there are two types, those that use antibodies – where there are millions of combinations of antibodies that can bind to the target of choice – and those that generate peptides that also connect to targets, and that's the t ype used by Israelis. The treatment was called muTaTo (multi-target toxin, or multi-target toxin).
"The concept is not new, but they may have adapted a system by modifying it, which other doctors have not yet been able to do. lack of data transparency But what all the world's experts are saying is that everything is still very embryonic, we can not judge the possible benefit of the research, "says immunologist Gollob.
READ ALSO
[ad_2]
Source link
